ADVERTISEMENT
Hep B Treatment and Associated HCC Risk
Tenofovir disoproxil (TDF) is linked to lower risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (HB), when compared to entecavir (ETV) treatment, a recent study revealed.
Both TDF and ETV can reduce the risk of HCC, but when compared in patients with chronic HB during a systematic review, researchers found adults treated with TDF over ETV had a lower risk of HCC.
“We searched multiple electronic databases from January 1, 1998, to October 31, 2019, for randomized controlled trials and observational comparative effectiveness studies in adults with CHB treated with ETV compared to TDF, reporting the incidence of HCC (minimum follow‐up 12 months),” the authors reported.
During the study, 1971 records were analyzed, including 14 studies (263,947 person-years). When analyzed against adjusted data—multivariate or propensity‐matched data—HCC risk within the group of patients treated with ETV was 27% higher than those treated with TDF.
“Additional analysis of adjusted data when separately reported among patients with cirrhosis demonstrated an adjusted HR of 0.90 (95% CI, 0.66‐1.23), suggesting no difference between ETV‐treated and TDF‐treated groups,” the authors concluded.
--Angelique Platas
Reference
Dave S, Park S, Murad MH, et al. Comparative effectiveness of entecavir versus tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis b: a systematic review and meta‐analysis AASLD 2021; 73(1)68-78
